chrisvoncsefalvay/vaers-outcomes huggingface dataset:
COVID-19; COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 69-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), as dose 3 (booster), single (Batch/Lot number: unknown), in right arm for covid-19 immunisation. The patient's relevant medical history included: "known allergies: Penicillin" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary immunization complete but manufacturer unknown), for COVID-19 Immunization. The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant), outcome "unknown" and all described as "COVID-19". Therapeutic measures were taken as a result of suspected covid-19. Clinical Information: Report about covid treatment. No Other medication in 2weeks. Antiviral details reported as, Product- COVID 19 Treatment, Brand was Paxlovid, Treatment start date was 27Apr2022 and Treatment stop date was reported as 02May2022, Indication reported as Treatment of COVID-19. Vaccine lot unknown reason mentioned as Misplaced/discarded. Adverse event reported as, I had about 12 days after testing and feeling better after completion of Paxlovid, I became very tired, noticed my glands were swollen and sore in my neck on the right side. Again started coughing, and having nasal congestion and night sweats, Adverse event start date reported as 06May2022, Patient was Recovering, No treatment AE.  The information on the batch/lot number for [BNT162B2] has been requested and will be submitted if and when received.
Information has been received from a physician concerning a 16 year old female who on 16-JUN-2007 was vaccinated with a dose of Gardasil. Concomitant therapy included Vaqta also given on 16-JUN-2007. On 16-JUN-2007. On 16-JUN-2007 after being administered the vaccines the patient fainted and fell forward and hit her head. Unspecified medical attention was sought. Unspecified blood and urinary tests were performed, results not reported. At the time of the report her head and neck hurts (its' sore). Additional information has been requested.
10:35m: Checked on Pt. Redness noted @ injection site. C/O tinging and ice pack applied.  SpO2: 98% P: 69 BP: 144/88 Redness at injection Site/Tingling  BP: 124/82 10:50am: Checked on Pt. told to admin. Benadryl 25mg PO 11:05am: Pt doing better. cleared to go.
May 3rd I started feeling really tired and had a headache. May 4th, I felt like I had the flu. I had  a sore throat, head congestion and a weird headache which I also remember having after receiving my vaccine. I tested for Covid at home and that was positive. I stayed in bed for the next two days with a fever, achiness, and extreme fatigue. I also had a severe cough that would induce vomiting. The following week I ended up calling my doctor to see if they thought a steroid would help with my cough because it had become almost intolerable. He did not recommend the steroid but advised that I use over the counter medication to treat my symptoms. He also prescribed Tessalon Perles. My other symptoms have gone away at this point but my cough still lingers, although it isn't as bad as it was before.
Information has been received from a female consumer who was vaccinated with a dose of RECOMBIVAX HB (manufacturer unspecified) when she was around 21 years of age. Subsequently the patient experienced vision problem on an unspecified date. No other details provided. This is one of several reports received form same source. Additional information has been requested.
second dose and is still feeling wonderful/feels wonderful/after the first dose noticed that the joints didn't hurt for a couple days/after first dose noticed that muscles didn't hurt for a couple days/"I don't ever feel good/I feel 20 years young; soreness at the site of injection after first dose; pain at the site of injection after first dose; This spontaneous case was reported by a consumer and describes the occurrence of THERAPEUTIC RESPONSE UNEXPECTED (second dose and is still feeling wonderful/feels wonderful/after the first dose noticed that the joints didn't hurt for a couple days/after first dose noticed that muscles didn't hurt for a couple days/"I don't ever feel good/I feel 20 years younger), MYALGIA (soreness at the site of injection after first dose) and VACCINATION SITE PAIN (pain at the site of injection after first dose) in a 74-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 049E21A) for COVID-19 vaccination.     Concurrent medical conditions included Cramps, Coronary artery disease and Pain (before the vaccine). Concomitant products included AMLODIPINE BESILATE (NORVASC) for Coronary artery disease, OMEPRAZOLE for Stomach cramps, CLOPIDOGREL BISULFATE (PLAVIX) and ROSUVASTATIN CALCIUM (CRESTOR) for an unknown indication.    On 07-Sep-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In September 2021, the patient experienced THERAPEUTIC RESPONSE UNEXPECTED (second dose and is still feeling wonderful/feels wonderful/after the first dose noticed that the joints didn't hurt for a couple days/after first dose noticed that muscles didn't hurt for a couple days/"I don't ever feel good/I feel 20 years younger), MYALGIA (soreness at the site of injection after first dose) and VACCINATION SITE PAIN (pain at the site of injection after first dose). At the time of the report, THERAPEUTIC RESPONSE UNEXPECTED (second dose and is still feeling wonderful/feels wonderful/after the first dose noticed that the joints didn't hurt for a couple days/after first dose noticed that muscles didn't hurt for a couple days/"I don't ever feel good/I feel 20 years younger) outcome was unknown and MYALGIA (soreness at the site of injection after first dose) and VACCINATION SITE PAIN (pain at the site of injection after first dose) was resolving.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient was taking concomitant medications for cramps and coronary artery problems. No treatment medications were reported.   This case was linked to MOD-2021-346886 (Patient Link).
This case was reported by a healthcare professional and described the occurrence of itchy rash in a 46-year-old female subject who was vaccinated with BOOSTRIX, (GlaxoSmithKline).  Concurrent medical conditions included high cholesterol.  Concurrent medications included Multivitamins (Vitamins).  On 22 February 2010 at 14:00 the subject received unspecified dose of BOOSTRIX (.5 ml, unknown, left deltoid).  On 24 February 2010, 2 days after vaccination with BOOSTRIX, the subject experienced itchy rash.  The healthcare professional reported the subject has been experiencing an itchy rash off and on since receiving BOOSTRIX.  At the time of reporting the itchy rash was unresolved.  Follow-up information was received on 20 April 2010, via healthcare professional who indicated the itchy rash started on 10 March 2010 as opposed to the previously reported 23 February 2010.  The itchy rash had improved.  The subject had no adverse following previous vaccinations.
see a small point when i move my eye; This is spontaneous report from a contactable consumer. This consumer (patient) of an unspecified age reported for herself that she received bnt162b2 (BNT162B2, Solution for injection), dose 1 via an unspecified route of administration on 09Mar2021 (Batch/Lot number was not reported) as SINGLE DOSE, dose 2 via an unspecified route of administration on 28Mar2021 (Batch/Lot number was not reported) as SINGLE DOSE for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The patient experienced see a small point when i move my eye on an unspecified date. Since i got the 1st dose there is something going on with my left eye. I see a small point when i move my eye, I had an eye exam on 8FEB2021 and it was not there. Has this been reported and what should i do? The patient underwent lab tests and procedures which included ophthalmological examination: unknown on 08Feb2021. The action taken in response to the event for bnt162b2 was not applicable. The outcome of the events was reported as unknown.  No Follow-up attempts are needed. Information about lot/batch number cannot be obtained.
During 15 minute observation following the Moderna vaccination. Client complained  feeling itchy, redness/ flushing noted to her face. Also reported  that her throat felt like it was tightening and swelling.  Staff provided her with 25 mg Benadryl at 2:20  and another 25 mg dose at 2:50. Following the second dose client reported that tightness in her throat decreased. Flushing and redness of her face also decreased.  Blood pressure was 155/88  pulse 102  and 99% O2 Sats
This spontaneous report was received from a registered nurse and refers to an unspecified number of patients of unknown age and gender. The patients' concurrent conditions and medical history were not reported. On unknown dates, the patients were vaccinated with improperly stored M-M-R II injection, lot # L002242, expiration date: 21-JAN-2017, therapy type: rHA (exact dose and route of administration were not reported). There were no concomitant medications provided. There were no adverse effects reported. Administered doses of vaccines experienced the temperature excursion of 9 degrees Celsius for 120 hours. There was no previous temperature excursion. This is one of several reports received from the same reporter. Additional information is not expected as reporter refused additional contact.
Information has been received from a physician concerning his wife who on an unspecified date was vaccinated with a dose of ZOSTAVAX (Merck) (route and administration site not reported).  Subsequently the patient developed a rash on her entire arm.  It was not specified which arm was affected.  Additional information has been requested.
Dizziness and feeling generally disconnected. Difficulty focusing. These symptoms occurred 1 day after the shot. No outcome determined yet as I am submitting this right as I am experiencing it.
~1 day post #3 Anthrax Vax.  Pt developed large 150mm indurated, pyretic lesion over injection sight that extended to elbow.  Resolved with oral Prednisone and topical Timovate.  Pt had prior reactions to previous 2 doses only marked less severe.
Mother stated patient had large knot in arm where vaccine was given.  Arm was reddened around area, and hot to touch.  IBU given 10/29/2015, with little improvement on 10/30/2015.  By Nov. 2, patient was much improved, but still had large knot at injection site along with redness at site.
Within 10 minutes, severe headache and fatigue. Treated with ibuprofen. Later, that evening,  fever and lethargy and swollen face. Treated with ibuprofen, ZYRTEC, BENADRYL. All but swollen face resolved by next am, and swollen face resolved by following day.
PATIENT STATES HE GOT THE 1ST DOSE . HE  GOT RASH  AND SWOLLEN  ON BOTH HANDS.  IT WENT AWAY AFTER A WEEK OR SO.  HE GOT THE SECOND DOSE AND SAME THING HAPPENED.  HOWEVER AFTER A FEW WEEKS IT RESOLVED.  NOW IT CAME BACK AGAIN.  HE ALSO HAD ULCERS IN HIS MOUTH
vaccines have undergone several temperature excursions and have been administered to patient; No adverse event; vaccines have undergone several temperature excursions and have been administered to patient; This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (vaccines have undergone several temperature excursions and have been administered to patient), POOR QUALITY PRODUCT ADMINISTERED (vaccines have undergone several temperature excursions and have been administered to patient) and NO ADVERSE EVENT (No adverse event) in a 2-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AS1412B) for COVID-19 prophylaxis.     It was unknown if patient had ever been diagnosed or tested positive for COVID-19.     On 04-Aug-2022 at 5:03 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .25 milliliter. On 04-Aug-2022 at 5:03 PM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (vaccines have undergone several temperature excursions and have been administered to patient). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (vaccines have undergone several temperature excursions and have been administered to patient) and NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (vaccines have undergone several temperature excursions and have been administered to patient), POOR QUALITY PRODUCT ADMINISTERED (vaccines have undergone several temperature excursions and have been administered to patient) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for PRODUCT TEMPERATURE EXCURSION ISSUE (vaccines have undergone several temperature excursions and have been administered to patient) and POOR QUALITY PRODUCT ADMINISTERED (vaccines have undergone several temperature excursions and have been administered to patient).    Patient received vaccine in deltoid.  Concomitant medication list was not provided. It was reported that refrigeration excursions identified, vaccines stored in the refrigerator that underwent several temperature excursions going back to Aug-2022.state vaccine was housed in these units. There were excursions noted. Manufactures were notified and the state department was made aware of the situation No adverse reactions reported to their knowledge for any of these patients. Storage condition at the time of the excursion was refrigerated. Individual vials or unbroken cartons were 2 unbroken cartons 20 vials. Vial was moved from freezer to refrigerator on 07-Sep-2022. Vials were not visualized.  Treatment information was not provided.
Pregnancy at time of vaccination; This spontaneous prospective pregnancy case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of EXPOSURE DURING PREGNANCY (Pregnancy at time of vaccination) in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031L206) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on 16-Nov-2020 and the estimated date of delivery was 28-Aug-2021. On 17-Feb-2021, the patient experienced EXPOSURE DURING PREGNANCY (Pregnancy at time of vaccination). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  thirteenth week of the pregnancy. The delivery occurred on an unknown date, which was reported as Unknown. For neonate 1, The outcome was reported as Unknown. At the time of the report, EXPOSURE DURING PREGNANCY (Pregnancy at time of vaccination) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No  concomitant medical  provided by the reporter. No treatment medication provided by the reporter.
5 minutes after shot, patient had tingling all over body. after 15 minutes, headache and chest tightness
loose stools; Fatigue; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 54 year-old female patient (not pregnant) received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), administered in arm right, administration date 17Mar2021 15:30 (Lot number: en6203) at the age of 54 years as dose 2, single for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (dose 1, lot number: EL3247, location: rt arm), administration date: 24Feb2021, when the patient was 54 years old, for COVID-19 immunization. The following information was reported: DIARRHOEA (non-serious) with onset 18Mar2021 09:00, outcome "recovered", described as "loose stools"; FATIGUE (non-serious) with onset 18Mar2021 09:00, outcome "recovered", described as "Fatigue". Therapeutic measures were not taken as a result of diarrhoea, fatigue. Additional information: The patient received no other medications within 2 weeks of vaccination. The patient was not diagnosed with COVID-19 prior to vaccination. Patient has not been tested for COVID-19 since the vaccination. No allergies to medications, food, or other products.  No follow-up attempts are possible. No further information is expected.
Hives; Pain in injection arm; Redness; Swelling; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE PAIN (Pain in injection arm), INJECTION SITE ERYTHEMA (Redness), INJECTION SITE SWELLING (Swelling) and INJECTION SITE URTICARIA (Hives) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. UnknownUnknown) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included MULTIVITAMIN [VITAMINS NOS], ESOMEPRAZOLE MAGNESIUM (NEXIUM 24HR), FUROSEMIDE (LASIX P) and ATORVASTATIN CALCIUM, EZETIMIBE (STATIN EZ) for an unknown indication.    On 22-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Jan-2021, the patient experienced INJECTION SITE PAIN (Pain in injection arm), INJECTION SITE ERYTHEMA (Redness) and INJECTION SITE SWELLING (Swelling). On 29-Jan-2021, the patient experienced INJECTION SITE URTICARIA (Hives). At the time of the report, INJECTION SITE PAIN (Pain in injection arm), INJECTION SITE ERYTHEMA (Redness), INJECTION SITE SWELLING (Swelling) and INJECTION SITE URTICARIA (Hives) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Pt vaccinated with Pneumovax became very dizzy buzzing in head, nausea. Pt also has Meniere's disease.  Treatment: observation, Antivert & Compazine.
R arm swelling and erythema, mild irritation and soreness. Not painful. Erythema below deltoid to mid upper arm on lateral side. Treatment - warm compressions to R arm 2-3 x per day, Ibuprofen 400 mg evert 8 hrs PRN.
4/17/21 - Started with burning on arms and legs.4/18 and 4/19 - pain and burning everywhere on body, fever, head ache .Felt like I was going to die. 4/20/21 - fever, severe headache, pain and burning everywhere - urinary retention started.4/21//21 - Went to ER - had not voided in 18 hours. Fever, pain every body part, every joint skin burning, back and chest red and itching.
Recently referred to clinic on May 6 for a diagnosis of bilateral posterior uveitis made by retinal ophthalmology for which he is being treated with ocular steroids.  Original diagnosis of bilateral posterior uveitis was made by retinal ophthalmology around April 29.
Injection sites-no reaction. On 12/19/16 at 1030 pt came into clinic with parents and cousin of father. Parents relayed high fever started 12/16/16, vomited 12/17/and 12/18, checked pt's temp at 1035 101.2F temporal parents wondering if illness from vaccines received 12/15/16. I saw pt's arms-no site reaction. Recommended parents take to a walk in or ER.
increase in tinnitus; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 55 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 25Mar2021 15:00 (Lot number: ER8730) at the age of 55 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "cancer" (unspecified if ongoing); "two stem cell transplants" (unspecified if ongoing). Concomitant medication(s) included: METOPROLOL; PRAVASTATIN; LEVOTHYROXINE; ZYRTEC [CETIRIZINE HYDROCHLORIDE]. The following information was reported: TINNITUS (non-serious) with onset 25Mar2021, outcome "unknown", described as "increase in tinnitus". Therapeutic measures were not taken as a result of tinnitus.  Additional information: I have noticed recent increase in tinnitus that may have started after the first vaccine. Patient did not receive any other vaccine within four weeks of COVID-19 vaccine. The patient did not have COVID prior vaccination and not tested post vaccination for Covid.   No follow-up attempts are possible. No further information is expected.
This spontaneous report was received from a physician via a company representative regarding a female patient of unknown age with medical history of lupus. Patient's drug reactions or allergies were not provided. On an unknown date, the patient was vaccinated with a dose of ZOSTAVAX (dose, route and lot number were not provided). Concomitant medications included unspecified immunosuppressive therapy for her lupus. On an unknown date, after the patient received ZOSTAVAX. The patient received unspecified antiviral and pain medication as treatment for the adverse event. At the time of the report, the patient's outcome and the causality were unknown. Additional information is not expected because the reporter did not want to be contacted.
Pt experienced paleness, sweating, cold hands, nausea, dizziness and lightheadedness.
Tested positive to COVID; Tested positive to COVID; This is a spontaneous report from a contactable nurse, the patient. A 41-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), via an unspecified route of administration on 23Dec2020 as a single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. On 02Jan2021, the patient tested positive to Covid. The outcome of the event, tested positive to Covid, was unknown.   The lot number for the vaccine, BNT162B2, was not provided and will be requested during follow up.
Severe flu like symptoms for 2 days initially.  I now have an erratic heartbeat and blood pressure with periodic AFib
The night after taking the vaccine, I had uncontrollable chills for several hours. The shivers continued even when I seemed to fall asleep, as my roommate stated. When I woke up, I had a high fever, extreme muscle aches, nausea, and was unable to move. The next day, I felt better. I did feel drowsy and almost like I could not think properly. After that, the symptoms went away.
Less than two weeks after receiving the 2nd dose of the vaccine, I started A-Fib.  My heart was consistently beating at around 200 BPM.  I was taken by ambulance to the ER.  The A-Fib continued for several hours.  I was admitted to the ICU.  My heart finally went into sinus rhythm later that evening after receiving medication to get it into rhythm.  I now have A-fib episodes on a daily basis.  There is no family history of coronary heart disease of any kind.  I have not had any symptoms of a-fib prior to receiving the Pfizer Covid19 vaccination.
The patient returned to the pharmacy after one week and the site of injection was red, hot and itching.